Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haNK
- Development stage
- Phase 2
- Lead developer
- ImmunityBio
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intratumoral
01
Overview
haNK is a proprietary, genetically engineered human natural killer (NK) cell therapy platform developed for cancer immunotherapy. These NK cells are modified to express a high-affinity Fc receptor (CD16/FcγRIIIa), enabling them to bind more effectively to the Fc region of therapeutic antibodies and enhance antibody-dependent cellular cytotoxicity (ADCC) against tumor cells. The haNK platform is designed to be used alone or in combination with monoclonal antibody therapies, aiming to improve the targeting and elimination of cancer cells. Clinical development has included phase I trials for solid tumors, with further advancements leading to t-haNK variants that incorporate chimeric antigen receptors for additional specificity[5][6].
- Brand names
- haNK Cells
- Other names
- high affinity NK
02
Targets
IgG1 Fc (Immunoglobulin G1 Fc region)
Beyond the preview
Go deeper on haNK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haNK.